患有阿特佐利祖马布诱导的脑炎的患者在肝细胞癌中
Kakeru Otomo1, Masashi Fujita1, Ryoji Sekine1
1Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
Internal medicine (Tokyo, Japan)
|September 11, 2024
概括
阿特佐利祖马布诱导的脑炎是癌症免疫疗法的罕见但严重的副作用. 早期诊断和类固醇治疗可以导致快速康复,改善患者的治疗结果.
科学领域:
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
- 肝细胞癌治疗方法 肝细胞癌治疗方法
背景情况:
- 肝细胞癌 (HCC) 通常用免疫疗法治疗,包括阿特佐利祖马布和贝瓦西祖马布.
- 这些治疗可能会发生与免疫相关的不良事件 (irAEs).
- 神经性irrAEs,如脑炎,是罕见的,但至关重要的.
研究的目的:
- 在HCC患者中报告由阿特佐利祖马布加贝瓦齐祖马布诱导的脑炎病例.
- 为强调早期诊断和对这种罕见不良事件的及时治疗的重要性.
主要方法:
- 一名65岁的HCC男性患者在阿特佐利祖马布加贝瓦齐祖马布治疗后出现了神经症状.
- 诊断工作包括成像和脑脊液分析.
- 治疗包括立即高剂量的类固醇脉冲疗法.
主要成果:
- 患者发烧,运动困难和失言症,进展到昏迷状态.
- 恶性和感染被排除在外,导致诊断为阿特佐利祖马布诱导的脑炎.
- 类固醇脉冲疗法导致神经系统迅速改善,恢复了意识,并有能力走路和说话.
结论:
- 在接受这种免疫治疗的患者中,阿特佐利祖马布诱导的脑炎是一个关键的诊断.
- 及时识别和启动类固醇脉冲疗法对于有利的结果至关重要.
- 早期干预可以显著改善预后,并允许继续癌症治疗.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
354
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
354
Drug Toxicity: Risk factors
210
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
210
Drug toxicity: Idiosyncratic Reactions
197
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197


